DWDonna M. Weber

Donna M. Weber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Donna M. Weber has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Advances and practical use of monoclonal antibodies in multiple myeloma therapy

    by Hans C. Lee, Donna M. Weber

    The use of proteasome inhibitors and immunomodulatory agents in the treatment of myeloma have resulted in significant improvements in patient outcomes over the last decade. Although these agents now form the backbone of current myeloma treatment regimens both in the frontline and in a relapsed setting, drug resistance remains an inevitable challenge that most patients will encounter during their disease course. Hence, new treatment strategies continue to be explored, and the recent regulatory approvals of the monoclonal antibodies (mAbs) daratumumab (DARA) and elotuzumab (ELO), which target the plasma cell surface proteins CD38 and signaling lymphocytic activation molecule F7 (SLAMF7), respectively, have heralded the long-awaited era of antibody-based approaches in the treatment of myeloma. Hoping to build on these advances, a number of other mAbs are in various stages of clinical development, including those targeting myeloma cell surface antigens, the bone marrow microenvironment, and immune effector T cells such as anti-programmed cell death protein 1 antibodies. In this review, the current landscape and practical use of mAb-based therapy in myeloma will be discussed.


  • Depth of response post autologous hematopoietic stem cell transplantation (auto-HCT) to predict outcome in high risk multiple myeloma (MM).

    by Bei Hu, Koji Sasaki, Qaiser Bashir, Nina Shah, Krina K. Patel, Uday R. Popat, Chitra Hosing, Yago Nieto, Pei Lin, Ruby Delgado, et al.

    8019 Background: Despite major advances in the treatment for MM, patients (pts) with high risk disease (HRD) have significantly worse outcomes. Emerging data supports the importance of the depth of response on the outcome, including negative minimal residual disease (MRD-) status by multiparametric flow cytometry (MFC). Methods: 416 newly diagnosed pts with symptomatic MM received bortezomib-based induction, followed by auto-HCT between 1/1/2005 and 12/31/2013 at our institution. Pts with t(4:14), t(14;16), del 17p, del 1p and/or amplification 1q by cytogenetics or FISH were defined as HRD; all others were standard risk (SRD). MFC was performed on bone marrow to detect MRD before and after auto-HCT in select pts. Primary endpoints were complete remission (CR), MRD status, progression free survival (PFS), and overall survival (OS). Results: Eighty pts (19%) were HRD; 336 (81%) were SRD. 64 (80%) HRD and 260 (77%) SRD pts received maintenance therapy post auto-HCT. After induction, 10 (13%) HRD and 32 (10%) SRD pts were in CR. This increased to 17 (21%) HRD and 98 (29%) SRD pts in CR after auto-HCT. Three to 24 months post maintenance, CR was achieved in 23 (29%) HRD and 141 (42%) SRD pts. 229 pts (50 HRD, 179 SRD) had MRD data post-auto-HCT. Twenty-five (50%) HRD and 121 (68%) SRD pts achieved MRD- status (p = 0.03). After a median follow up of 33.4 months, median PFS in the HRD and SRD group was 24.8 and 45.5 months, respectively (p = 0.0003). Median OS in HRD and SRD group was 68.6 months and not reached, respectively (p < 0.001). MRD- status was associated with longer PFS on univariate analysis (p = 0.003), but longer PFS or OS was not seen on multivariate cox proportional hazards analysis (MVA) with time-dependent covariates. The only two independent factors that were associated with shorter PFS and OS on MVA were HRD disease (HR for PFS = 3.2, p = 0.007; HR for OS = 2.9, p < 0.001) and lack of stringent CR post maintenance (HR for PFS = 8.6, p = 0.04; HR for OS = 4.4, p = 0.03). Conclusions: Even with bortezomib-based induction, upfront auto-HCT, and maintenance in 80% pts, the PFS and OS is significantly shorter in pts with HRD. Achievement of a deeper response post-maintenence therapy is associated with better outcome.

  • Open Access

    Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis

    by Xin Cao, Qing Ye, Robert Z. Orlowski, Xiaoxiao Wang, Sanam Loghavi, Meifeng Tu, Sheeba K. Thomas, Jatin Shan, Shaoying Li, Muzaffar Qazilbash, et al.

    The prognostic importance of extramedullary involvement in patients with Waldenström macroglobulinemia (WM) at diagnosis and treatment options for these patients has not been well evaluated. In this study, we investigated the clinical manifestations, biological features, and effect of first-line therapy on the outcome of WM patients diagnosed with extramedullary involvement (EMWM) vs those with only bone marrow involvement (BMWM). We analyzed the clinical data of 312 WM patients diagnosed with EMWM (n = 106) and BMWM (n = 206) at The University of Texas MD Anderson Cancer Center from 1994 to 2014. EMWM was confirmed by biopsy, positron emission tomography–computed tomography, or magnetic resonance imaging, and clinical laboratory analyses. Characteristics associated with EMWM were male sex (P = 0.027), age younger than 65 years (P = 0.048), presence of B symptoms (P < 0.001), high serum beta-2 macroglobulin (P < 0.001) level, low serum albumin level (P = 0.036), and cytogenetic abnormalities (P = 0.010). Kaplan-Meier survival analysis results showed that EMWM patients had a significantly shorter median overall survival (P < 0.001) and progression-free survival (PFS) (P < 0.001) than did BMWM patients. Chemotherapy combined with targeted therapy improved PFS for BMWM patients (P = 0.004) but not for EMWM patients. Additionally, initial treatment with rituximab significantly improved the PFS of BMWM patients (P = 0.012) but had no effect on EMWM patients. However, EMWM patients treated with nucleoside analogs attained a better PFS than those who did not (P = 0.021). We show that extramedullary involvement at diagnosis is an adverse prognostic factor in WM patients and that first-line therapy with nucleoside analogs improved PFS for patients with EMWM. The study provides unique clinical and treatment observations in subtypes of WM patients.


  • Open Access

    Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study

    by M Kay Garcia, Lorenzo Cohen, Ying Guo, Yuhong Zhou, Bing You, Joseph Chiang, Robert Z Orlowski, Donna Weber, Jatin Shah, Raymond Alexanian, et al.

    This single-arm study evaluated feasibility, safety, and initial efficacy of electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy (PN) in cancer patients with multiple myeloma. Patients with neuropathy ≥ grade 2 received 20 acupuncture treatments over 9 weeks. For the 19 evaluable patients, Functional Assessment of Cancer Therapy/Gynecological Oncology Group-Neurotoxicity (FACT/GOG/NTX) mean (SD) scores improved significantly between baseline and week 13 (20.8 [9.6] vs 13.2 [8.5], p = 0.0002). Moderate effect size differences began on week 4, with the largest effect size differences found at week 9 for FACT/GOG/NTX scores, worst pain in the last 24 hours, and pain severity (Cohen’s d = 1.43, 1.19, and 1.08, respectively) and continuing through week 13 (Cohen’s d = 0.86, 0.88, and 0.90, respectively). From baseline to week 13, additional significant improvements were seen as follows: postural stability (1.0 [0.6] vs 0.8 [0.4], p = 0.02); coin test (10.0 [7.4] vs 5.6 [1.9], p < 0.0001); button test (96.1 [144.4] vs 54.9 [47.3], p < 0.0001); and walking test (21.6 [10.0] vs 17.2 [7.7], p = 0.0003). No significant changes were seen with NCS. Acupuncture may help patients experiencing thalidomide- or bortezomib-induced PN. Larger, randomized, clinical trials are needed. ClinicalTrials.gov Identifier: NCT00891618 .


  • Multiple Myeloma

    by Donna Weber, Raymond Alexanian

  • Open Access

    Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

    by Qaiser Bashir, Hassan Khan, Robert Z. Orlowski, Ali Imran Amjad, Nina Shah, Simrit Parmar, Wei Wei, Gabriela Rondon, Donna M. Weber, Michael Wang, et al.

    A total of 149 patients with multiple myeloma (MM) who received allogeneic hematopoietic stem cell transplantation (allo‐HCT) with myeloablative (MAC; n = 38) or reduced‐intensity conditioning (RIC; n = 110) regimens at MD Anderson Cancer Center were evaluated. Of the total, 120 (81%) patients had relapsed or had refractory disease. Median age of MM patients was 50 (28–70) years with a followup time of 28.5 (3–164) months. The 100‐day and 5‐year treatment related mortality (TRM) rates were 17% and 47%, respectively. TRM was significantly lower with RIC regimens (13%) vs. 29% for MAC at 100 days (P = 0.012). The cumulative incidence of Grade II–IV acute graft‐versus‐host disease (GVHD) was 35% and chronic GVHD was 46%. PFS and OS at 5 years were 15% and 21%, respectively. In multivariate analysis, allo‐HCT for primary remission consolidation was associated with longer PFS (HR 0.35; 95% CI, 0.18–0.67) and OS (HR 0.29; 95% CI 0.15–0.55), while absence of high‐risk cytogenetics was associated with longer PFS only (HR 0.59; 95% CI 0.37–0.95). We observe that TRM has decreased with the use of RIC regimens, and long‐term disease control can be expected in a subset of MM patients undergoing allo‐HCT. Further studies should be conducted in carefully designed clinical trials in this patient population. Am. J. Hematol., 2012.


  • Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

    by Qaiser Bashir, Nina Shah, Simrit Parmar, Wei Wei, Gabriela Rondon, Donna M. Weber, Michael Wang, Robert Z. Orlowski, Sheeba K. Thomas, Jatin Shah, et al.

    We retrospectively analyzed the outcomes of all consecutive patients with myeloma (n = 84) aged ≥70 years who had received autologous hematopoietic stem cell transplant (auto HCT) between July 1999 and June 2010 at our institution. The median age at auto HCT was 72 years, the median number of prior therapies was 2.5 and the median time from diagnosis to auto HCT was 10.2 months. The conditioning regimen consisted of melphalan at 140 mg/m2 in 10%, 180 mg/m2 in 25% and 200 mg/m2 in 65% of patients. The day-100 non-relapse mortality was 3%. The overall response rate at day 100 was 85% (complete response 18%, very good partial response 12%, partial response 55%). After a median follow-up of 25 months among surviving patients, the estimated progression-free survival and overall survival at 5 years were 27% and 67%, respectively. The incidence of grade II–IV toxicity, response rate and survival were similar across three melphalan dose levels. These results indicate that high-dose melphalan plus auto HCT is safe and feasible for patients with multiple myeloma aged ≥70 years and age alone should not be an exclusion criterion for auto HCT.


  • Advances in treatment for relapses and refractory multiple myeloma

    by Tiffany Richards, Donna Weber

    Recent advances in the treatment of multiple myeloma have resulted in improved response rates and overall survival in patients with multiple myeloma. These advances are largely due to thalidomide-, lenalidomide-, and bortezomib-based combinations that have improved response rates, not only in patients with untreated disease, but also in those with relapsed and/or refractory myeloma, in some cases producing response rates up to 85%. Eventually, however, nearly all patients relapse, emphasizing a continuing role for the introduction of investigational agents that overcome drug resistance. This article will review the current role for thalidomide, lenalidomide, and bortezomib-based combinations, as well as some preliminary findings for promising investigational agents currently in clinical trials for patients with relapsed and/or refractory disease.


  • Top Cited Papers

    Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

    by Donna M Weber, Christine Chen, Ruben Niesvizky, Michael Wang, Andrew Belch, Edward A Stadtmauer, David Siegel, Ivan Borrello, S Vincent Rajkumar, Asher Alban Chanan-Khan, et al.

    Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma. Patients in the United States and Canada who had received at least one previous therapy for multiple myeloma but who required additional treatment were randomly assigned to receive either 25 mg of lenalidomide or placebo on days 1 to 21 of a 28-day cycle. Both groups also received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles. After the fourth cycle, 40 mg of dexamethasone was administered only on days 1 to 4. Safety, clinical response, time to progression, and overall survival were assessed. We assigned 177 patients to the lenalidomide group and 176 to the placebo group. Complete, near-complete, or partial responses occurred in 108 patients (61.0%) in the lenalidomide group and in 35 patients (19.9%) in the placebo group (P<0.001); complete responses occurred in 14.1% and 0.6%, respectively (P<0.001). The median time to progression was 11.1 months in the lenalidomide group and 4.7 months in the placebo group (P<0.001). Median overall survival times in the two groups were 29.6 months and 20.2 months, respectively (P<0.001). Grade 3 or 4 adverse events were reported in 85.3% of the lenalidomide group and in 73.1% of the placebo group; these events resulted in study discontinuation in 19.8% and 10.2%, respectively. Grade 3 or 4 neutropenia and venous thromboembolism were more common in the lenalidomide group than in the placebo group (41.2% vs. 4.6% and 14.7% vs. 3.4%, respectively; P<0.001 for both comparisons). Lenalidomide plus dexamethasone is superior to placebo plus dexamethasone in patients with relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00056160.)


  • Novel Agents for Previously Untreated Multiple Myeloma

    by Sheeba Thomas, Tiffany Richards, Donna M. Weber